More Bad News for the Maker of Trasylol
Bayer AG, the maker of the anti-bleeding drug Trasylol, received more bad news yesterday when a federal judge in New Jersey invalidated a patent the company held the contraceptive Yasmin.
The ruling means not only that another company may be able to sell a generic version of the drug but it also calls into question whether a newer version of Yaz, which relies on the patent, will receive legal protection.
Bloomberg News reports that Yasmin is part of a group of contraceptives that brought in $1.58 billion worth of sales last year.
Ulle Woerner, an analyst at Landesbank Baden-Wuerttemberg in Stuttgart, Germany, told Bloomberg News in an interview, “Bayer's lacking a lot of positive news flow at the moment so the market is quite nervous.”
Part of the “news flow” includes recently released studies that show patients given the anti-bleeding drug Trasylol during heart surgery had a higher risk of death than patients given a comparable drug. Studies also underscore the increased chances of suffering kidney failure as a result of receiving Trasylol. And only a few weeks ago, a 60 Minutes segment noted that 1,000 lives a day could have been saved if Bayer and the FDA had pulled Trasylol from the market when flags were raised about the drug’s safety.
If you or a loved one suffered complications after taking Trasylol contact Carey & Danis. We can help. Carey & Danis is a national law firm that represents individuals injured by America's largest corporations.
For more information, fill out our online contact form or call Carey & Danis toll-free at 800-721-2519.
